XORTX Therapeutics company info

What does XORTX Therapeutics do?
XORTX Therapeutics (NASDAQ:XRTX) focuses on developing innovative therapies aimed at treating kidney disease and conditions that lead to kidney damage. It is traded on the NASDAQ stock exchange under the ticker symbol XRTX. The company is dedicated to advancing its clinical programs to address unmet medical needs in the treatment of progressive kidney disease. XORTX's projects primarily involve the development of therapeutic solutions that target the underlying causes of kidney damage, including high uric acid levels and oxidative stress. Their objective is to improve the quality of life for patients suffering from these debilitating conditions through the advancement of their research and development efforts. By leveraging its expertise in kidney health, XORTX is committed to bringing novel treatments to market that can offer hope and improved outcomes for patients facing kidney-related health challenges.
XORTX Therapeutics company media
Company Snapshot

Is XORTX Therapeutics a public or private company?

key
Ownership
Public

How many people does XORTX Therapeutics employ?

people
Employees
3

What sector is XORTX Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for XORTX Therapeutics?

location pin
Head Office
Calgary, Canada

What year was XORTX Therapeutics founded?

founded flag
Year Founded
2011
What does XORTX Therapeutics specialise in?
/Kidney Disease Therapy /Diabetic Nephropathy Treatment /Chronic Kidney Disease Research /Hyperuricemia Solutions /Drug Development /Biotechnology Innovations

What are the products and/or services of XORTX Therapeutics?

Overview of XORTX Therapeutics offerings
Development of novel therapeutics to treat progressive kidney disease in autosomal dominant polycystic kidney disease and other chronic kidney diseases.
Advancement of XRx-008 program for Alport syndrome, aiming to reduce hyperuricemia and improve kidney function.
Research on XRx-101, a formulation designed to mitigate acute kidney injury resulting from contrast media administration during medical procedures.
Exploration of treatments targeting uric acid pathways to address rare kidney diseases and potentially extend to more common renal ailments.
Investigation into metabolic syndrome interventions, focusing on therapeutics to manage and mitigate its impact on kidney health.
Pursuit of partnerships and collaborations to expand research and development efforts in kidney disease and related metabolic disorders.

Who is in the executive team of XORTX Therapeutics?

XORTX Therapeutics leadership team
  • Dr. Allen Warren Davidoff Ph.D.
    Dr. Allen Warren Davidoff Ph.D.
    Founder, CEO, President & Director
  • Mr. James Neville Fairbairn C.A., C.P.A., ICD.D
    Mr. James Neville Fairbairn C.A., C.P.A., ICD.D
    Interim Chief Financial Officer
  • Dr. Stephen  Haworth M.D., MRCP
    Dr. Stephen Haworth M.D., MRCP
    Chief Medical Officer
  • Dr. Stacy  Evans M.B.A., M.D.
    Dr. Stacy Evans M.B.A., M.D.
    Chief Business Officer
  • Nick  Rigopoulos
    Nick Rigopoulos
    Director of Communications
  • Dr. David  Sans M.B.A., Ph.D.
    Dr. David Sans M.B.A., Ph.D.
    Director of Corporate Development
  • Dr. David  MacDonald Ph.D.
    Dr. David MacDonald Ph.D.
    Consultant of Clinical Operations
  • Ms. Charlotte  May
    Ms. Charlotte May
    Corporate Secretary